Premier Alternatives

Halda Therapeutics

Drug Discovery · New Haven, CT · Founded 2018 · Privately Held (backing)

Developer of a drug discovery platform designed to create therapeutic and precision medicines. Halda Therapeutics is based in New Haven, CT and was founded in 2018. Its last known valuation is $3 billion. It has raised $227 million across 3 recorded rounds; the latest was a $126 million Series B in Jul 2024.

Last price · $/share
—
Implied valuation
$3.0B
Total raised
$227.1M
Last round
Later Stage VC (Series B)
Jul 2024

Halda Therapeutics key facts

  • Developer of a drug discovery platform designed to create therapeutic and precision medicines.
  • Halda Therapeutics’s last known valuation is $3.0B.
  • It has raised $227.1M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($126.5M) in Jul 2024.
  • Notable investors include RA Capital Management, Connecticut Innovations, Canaan Partners, Frazier Healthcare Partners, Deep Track Capital — 14 tracked in total.
  • Halda Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently Aug 2024 ($126.5M sold to 20 investors).
  • Status: Privately Held (backing).
Free account
More of Halda Therapeutics with a free account
  • ·The complete investor list: 14 names
  • ·Watch Halda Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Halda Therapeutics funding rounds

3 rounds
Jul 2024Later Stage VC (Series B)$126.5M▮
Dec 2021Early Stage VC$41.0MSEC filing▮
Feb 2019Early Stage VC$6.3MSEC filing▮
Full funding history →

Halda Therapeutics valuation

Halda Therapeutics's last known valuation is $3 billion. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Halda Therapeutics raised?

Halda Therapeutics has raised $227 million across 3 recorded rounds since 2019. The largest was a $6.3 million early-stage round in Feb 2019; the most recent was a $126 million Series B in Jul 2024.

Halda Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently in Aug 2024 ($126 million sold to 20 investors).

Halda Therapeutics investors

14 investors are on record for Halda Therapeutics, including RA Capital Management, Connecticut Innovations, Canaan Partners and Frazier Healthcare Partners. By type, the record holds 5 venture capital firms and 1 asset manager. The Series B in Jul 2024 drew 11 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Tubulis ($5.8 billion), Encoded Therapeutics ($1.8 billion) and Formation Bio ($1.7 billion).

About Halda Therapeutics

Developer of a drug discovery platform designed to create therapeutic and precision medicines. The company's platform focuses on the discovery of medicines through the creation of novel therapies that modify disease-causing pathways, enabling healthcare providers to treat their patients based on a novel therapeutic modality.

Industry
Drug Discovery
Sector
Healthcare
HQ
New Haven, CT, United States
Founded
2018
Employees
46
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$3.0B

Halda Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.